Australia's most trusted
source of pharma news
Posted 10 March 2026 AM
Roche partner Zealand Pharma has reported Phase 2 results for its much-hyped amylin analog which it described as positive, but which the market saw as disappointing, punishing the pharma by shaving a third off the share price.
The results showed petrelintide achieved up to 10.7 per cent mean body weight reduction at week 42 versus 1.7 per cent with placebo. Analysts were aiming for at least 12 per cent based on Lilly's pipeline asset eloralintide, which saw much higher weight loss in its phase 2 trial, and were reluctant to overlook the large difference.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.